MarketPulse

diabetes treatment

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lifeward Shareholders Back Oramed Partnership to Diversify Into Biotech

Lifeward gains shareholder approval for strategic Oramed deal, securing up to $47M capital while expanding into oral delivery technology.
LFWDORMPstrategic partnershipclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

DexCom Positioned as Hidden Beneficiary in GLP-1 Drug Expansion

DexCom benefits from GLP-1 drug expansion as CGM devices are increasingly prescribed together, unlocking significant untapped patient markets and complementary revenue opportunities.
DXCMhealthcare stocksmedical devices
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Strengthens Market Position With Weight-Loss Drug Success

Eli Lilly strengthens market position with blockbuster weight-loss drug Zepbound, diversified pipeline, and AI integration, supporting consistent financial performance and shareholder returns.
LLYdividend growthweight loss drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Therapeutics Market Poised to Exceed $33B by 2030 on Formulation Innovation

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.
PFELLYNVOAZNpersonalized medicinediabetes treatment